Transcription factor 7-like 2 (TCF7L2)

Transcription factor 7-like 2 (TCF7L2) is a high-mobility group (HMG) box-containing transcription factor that is a central component of the Wnt/β-catenin signaling pathway, where it regulates the expression of numerous genes involved in cell proliferation, differentiation, and glucose metabolism[1][2][4]. TCF7L2 is encoded by the TCF7L2 gene on chromosome 10q25.3 and is implicated as a major genetic risk locus for type 2 diabetes based on extensive genome-wide association studies[1][2]. The protein can act as a transcriptional activator or repressor depending on the presence of co-factors such as β-catenin, and distinct splice variants mediate tissue-specific functions[1][2]. Variants in TCF7L2 influence the risk of metabolic diseases, cancer progression, and response to specific antidiabetic therapies, making it both a clinically significant biomarker and a complex, context-dependent therapeutic target[1][2][4].

Other names

T-cell factor 4TCF-4hTCF-4TCF4HMG box transcription factor 4T-cell-specific transcription factor 4transcription factor 7-like 2 (T-cell specific, HMG-box)

Drugs (e.g., sulfonylureas) show response variability based on TCF7L2 genotype—mechanism mediated through modulation of target gene transcription and Wnt/β-catenin pathway activity[1] TCF7L2 variants alter cis-regulatory elements and gene expression in metabolic tissues